Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
Want to see MGTX full AI Analyst Report?
Top Page
Meiragtx Holdings
(NASDAQ:MGTX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$9.50
▼(-6.13% Downside)
Action:ReiteratedDate:04/24/26
The score is held down primarily by weak financial fundamentals—persistent losses, ongoing cash burn, and a weakened capital structure with negative equity—despite a notable 2025 revenue inflection. Technicals are moderately supportive with an intermediate-term uptrend but neutral momentum. Corporate events (financing, partnerships, and regulatory/clinical milestones) add a meaningful positive offset by improving runway and pipeline prospects, while valuation remains constrained by unprofitability.
Positive Factors
Revenue rebound & improved gross margin
A large 2025 revenue rebound with materially higher gross margins indicates the business can scale revenue with favorable unit economics. Sustained high gross margins improve the firm’s ability to leverage R&D and SG&A spending into eventual operating leverage, supporting longer-term path to profitability if revenue growth persists.
Negative Factors
Persistent cash burn & negative free cash flow
Ongoing negative operating and free cash flow means the company remains dependent on external financing to fund operations and late‑stage development. Even with year-over-year improvement, sustained cash burn constrains strategic flexibility, increases dilution risk, and requires continued successful capital markets access to execute plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound & improved gross margin
A large 2025 revenue rebound with materially higher gross margins indicates the business can scale revenue with favorable unit economics. Sustained high gross margins improve the firm’s ability to leverage R&D and SG&A spending into eventual operating leverage, supporting longer-term path to profitability if revenue growth persists.
Read all positive factors
Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$916.32M
Dividend YieldN/A
Average Volume (3M)814.83K
Price to Earnings (P/E)10.7
Beta (1Y)1.45
Revenue Growth144.57%
EPS Growth32.96%
CountryUS
Employees375
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding92,557,236
10 Day Avg. Volume1,246,061
30 Day Avg. Volume814,826
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue11.54
Enterprise Value/Gross Profit12.27
Enterprise Value/Ebitda-11.18
Forecast
1Y Price Target
$21.60Price Target Upside113.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.49
Revenue Forecast (FY)$86.20M
Meiragtx Holdings Business Overview & Revenue Model
Company Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia fo...
Meiragtx Holdings Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M |
| Gross Profit | 76.55M | 9.49M | 14.02M | 15.92M | 37.70M |
| EBITDA | -105.97M | -121.69M | -57.05M | -116.07M | -71.40M |
| Net Income | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
Balance Sheet | |||||
| Total Assets | 244.43M | 269.75M | 326.74M | 318.24M | 320.16M |
| Cash, Cash Equivalents and Short-Term Investments | 65.93M | 103.66M | 129.57M | 115.52M | 137.70M |
| Total Debt | 88.69M | 84.80M | 89.26M | 92.25M | 23.73M |
| Total Liabilities | 250.22M | 201.92M | 188.57M | 200.50M | 134.76M |
| Stockholders Equity | -5.79M | 67.83M | 138.18M | 117.74M | 185.40M |
Cash Flow | |||||
| Free Cash Flow | -50.19M | -109.45M | -125.54M | -118.06M | -65.75M |
| Operating Cash Flow | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M |
| Investing Cash Flow | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M |
| Financing Cash Flow | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M |
Meiragtx Holdings Technical Analysis
Positive
10.12
Price Trends
8.07
Positive
8.01
Positive
8.06
Positive
Market Momentum
0.69
Negative
60.25
Neutral
49.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 10.12 is above the 20-day moving average (MA) of 8.93, above the 50-day MA of 8.07, and above the 200-day MA of 8.06, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 60.25 is Neutral, neither overbought nor oversold. The STOCH value of 49.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.
Meiragtx Holdings Risk Analysis
Meiragtx Holdings disclosed 79 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Meiragtx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $6.12B | -39.92 | -20.02% | ― | ― | 8.38% | |
59 Neutral | $2.01B | -9.66 | -56.64% | ― | 17.28% | 5.36% | |
52 Neutral | $916.32M | 10.69 | 4438.87% | ― | 144.57% | 32.96% | |
52 Neutral | $544.70M | 5.60 | -31.75% | ― | 230194.59% | 20.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.39B | -9.06 | -34.48% | ― | ― | 41.14% |
* Healthcare Sector Average
MGTX
Meiragtx Holdings
9.90
4.49
82.99%
TSHA
Taysha Gene Therapies
6.98
5.08
267.37%
FDMT
4D Molecular Therapeutics
10.42
7.30
233.97%
TERN
Terns Pharmaceuticals
52.95
49.93
1650.41%
ERAS
Erasca
10.90
9.68
793.44%
Meiragtx Holdings Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
MeiraGTx Forms Strategic Gene Therapy Collaboration with Hologen
Positive
Apr 24, 2026
On April 20, 2026, MeiraGTx Holdings and affiliates completed the initial closing of a strategic collaboration with Guernsey-based Hologen Limited to jointly research, develop, manufacture and commercialize MeiraGTx’s AAV-GAD and AAV-BDNF ge...
Business Operations and StrategyPrivate Placements and Financing
MeiraGTx Announces Public Equity Offering to Fund Growth
Positive
Apr 16, 2026
On April 16, 2026, MeiraGTx Holdings plc entered into an underwriting agreement with BofA Securities, Inc. and Goldman Sachs Co. LLC for a public offering of 11,111,111 ordinary shares at $9.00 per share, with all shares sold by the company. The ...
Business Operations and StrategyPrivate Placements and Financing
MeiraGTx Reacquires Bota-Vec Rights, Advances XLRP Program
Positive
Apr 16, 2026
On April 15, 2026, MeiraGTx reacquired from Janssen all rights and related intellectual property to botaretigene sparoparvovec (bota-vec), an AAV-RPGR gene therapy for X-linked retinitis pigmentosa, for $25 million upfront plus potential milestone...
Business Operations and StrategyProduct-Related Announcements
MeiraGTx Reports Durable Phase 1 AQUAx Gene Therapy Data
Positive
Apr 16, 2026
On April 16, 2026, MeiraGTx reported three-year follow-up data from its Phase 1 AQUAx trial of AAV-hAQP1 in patients with grade 2/3 late radiation-induced xerostomia, showing the one-time gene therapy remained safe and well tolerated with no dose-...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances
Positive
Mar 26, 2026
On March 25, 2026, MeiraGTx amended its notes purchase and warrant agreements with Perceptive Credit Holdings, extending note maturity to May 2, 2027, committing to redeem $25 million of principal by June 30, 2026, and cutting the warrant exercise...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.